ArticleHealth and quality of life outcomes2012
Change in health status (EQ-5D) over 5 years among individuals with and without type 2 diabetes mellitus in the SHIELD longitudinal study.
Article in Health and quality of life outcomes, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- Health state utility values of type 2 diabetes mellitus and related complications: a systematic review and meta-regression.Health and quality of life outcomes · 2024Pooled it
- Pooled it
- Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6).Diabetes, obesity & metabolism · 2020Trial
- Health-related quality of life in people with type 2 diabetes participating in the LEADER trial.Diabetes, obesity & metabolism · 2019 · on this mapTrial
- Change in cardio-protective medication and health-related quality of life after diagnosis of screen-detected diabetes: Results from the ADDITION-Cambridge cohort.Diabetes research and clinical practice · 2015Trial
- Health-related quality of life changes in patients with Q-fever fatigue syndrome: a four-year follow-up study, 10 years post-infection.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Observational
- Modeling potential cost-effectiveness of tirzepatide versus lifestyle modification for patients with overweight and obesity.Obesity (Silver Spring, Md.) · 2025Article
- Epidemiology and Burden of Peripheral Artery Disease in People With Type 2 Diabetes: A Systematic Literature Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Review
- Sex differences in health-related quality of life among older Korean adults with type 2 diabetes mellitus: a cross-sectional study.Korean journal of community nutrition · 2024Article
- Utilities for Complications Associated with Type 2 Diabetes: A Review of the Literature.Advances in therapy · 2024Review
- Health Outcomes Following Engagement With a Digital Health Tool Among People With Prediabetes and Type 2 Diabetes: Prospective Evaluation Study.JMIR diabetes · 2023Article
- Health-related quality of life in Chinese individuals with type 2 diabetes mellitus: a multicenter cross-sectional study.Health and quality of life outcomes · 2023Article
- Health-Related Quality of Life Assessment in Older Patients with Type 1 and Type 2 Diabetes.Healthcare (Basel, Switzerland) · 2023Article
- Cost-effectiveness of second-line empagliflozin versus liraglutide for type 2 diabetes in the United States.Diabetes, obesity & metabolism · 2022Article
- Diabetic Foot Risk Assessment among Patients with Type 2 Diabetes in Kenya.The East African health research journal · 2022Article
- Article
- Evaluation of older people health passport implementation at primary health care centers in Saudi Arabia.Saudi medical journal · 2021Article
- Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.BMJ open diabetes research & care · 2021Article
- Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece.Clinical drug investigation · 2021Article
- Cost-effectiveness analysis of empagliflozin versus sitagliptin as second-line therapy for treatment in patients with type 2 diabetes in the United States.Diabetes, obesity & metabolism · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHealth-related quality of life studies among adults with type 2 diabetes mellitus, using the EQ-5D, have been short term and have not assessed change over years. This study assessed the change in health status and health-related quality of life over 5 years among individuals with and without diabetes.
methodsRespondents to the US Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes (SHIELD) completed the EuroQol-5D (EQ-5D) at baseline (2004) and 5 years later (2009). Visual analog scale (VAS) score and health index score were computed at baseline and year 5, and the change over 5 years was measured for individuals with type 2 diabetes mellitus (T2DM) and those without diabetes, and T2DM adults with and without diabetic complications. Linear regression models were used to determine change in EQ-5D score, controlling for age, gender, race, education, household income, and body mass index (BMI).
resultsThere was significantly greater decline in the EQ-5D index score in the T2DM group (-0.031 [SD 0.158]), compared with those without diabetes (-0.016 [0.141], p = 0.001). Compared with respondents without diabetes, those with T2DM had a larger reduction in EQ-5D index score, after controlling for demographics (p = 0.001). EQ-5D VAS score declined over 5 years for both groups: -1.42 (18.1) for the T2DM group, and -0.63 (15.8) for the group without diabetes, but the between-group difference was not significant either before (p = 0.09) or after (p = 0.12), controlling for demographics. T2DM respondents with diabetic complications had a greater decline in EQ-5D scores than T2DM respondents without complications (p < 0.05).
conclusionOver a 5-year period, health status of respondents with T2DM declined significantly compared with those with no diabetes, indicating that the burden of the disease has a long-term detrimental impact. This decline in health status is likely to impact utility scores (fewer quality-adjusted life years) for economic evaluations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.